Targeting deletions in cancer treatment is a promising area of research. The loss of specific tumor suppressor genes opens opportunities for developing therapies that either compensate for the lost function or target resulting vulnerabilities in cancer cells. For instance, cancers with synthetic lethality, where the loss of one gene makes cells reliant on another pathway for survival, can be exploited for designing targeted therapies. PARP inhibitors are an example of drugs that target synthetic lethal interactions in cancers with BRCA1/BRCA2 deletions.
